查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1974003

治疗性疫苗市场分析及预测（至2035年）：类型、产品类型、技术、应用、最终用户、组成部分、製程、部署模式、解决方案

Therapeutic Vaccines Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Component, Process, Deployment, Solutions
出版日期: | 出版商: Global Insight Services | 英文 489 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计治疗性疫苗市场规模将从2024年的638亿美元成长到2034年的1,768亿美元，复合年增长率约为10.7%。治疗性疫苗市场涵盖旨在透过刺激免疫系统增强其反应来治疗现有疾病的疫苗。与预防性疫苗不同，这些疫苗针对的是慢性感染疾病、癌症和自体免疫疾病。生物技术的进步和慢性病发病率的上升正在推动市场成长。关键发展包括个人化疫苗和新型递送系统，这些技术能够满足尚未满足的医疗需求，并展现出良好的治疗前景。

治疗性疫苗市场正经历强劲成长，这主要得益于免疫疗法的进步和慢性病盛行率的上升。癌症疫苗领域表现突出，这得益于针对肿瘤抗原的创新疗法。预防性疫苗，特别是针对人类乳突病毒 (HPV) 和肝炎的疫苗，由于公众意识的提高和预防策略的完善，发展势头强劲。感染疾病疫苗也紧跟着，针对爱滋病和结核病的新方法层出不穷。个人化疫苗正成为一个充满前景的领域，它能够根据个人的基因谱提供客製化的解决方案。佐剂技术正在提高疫苗的效力，并促进市场扩张。 mRNA疫苗的兴起及其近期取得的成功，预示着其快速研发和推广的潜力。自体免疫疾病疫苗细分市场也受益于疾病研究的进展，例如类风湿性关节炎。製药公司之间的策略联盟和合作正在促进创新并加速临床试验。监管政策的製定和支持进一步推动了市场动态，为未来的发展机会铺平了道路。

市场区隔
种类 癌症疫苗、感染疾病疫苗、自体免疫疾病疫苗、神经系统疾病疫苗
产品 预防性和治疗性疫苗
科技 重组技术、结合疫苗、减毒活病毒疫苗、去灭活疫苗、合成疫苗
适用的 肿瘤学、感染疾病、自体免疫疾病、神经系统疾病
最终用户 医院、诊所、研究机构、製药公司
成分 抗原、佐剂
流程 临床前试验、临床试验及生产製造
实施表格 本机部署、云端部署
解决方案 疫苗研发、疫苗生产、疫苗分发

市场概况：

治疗性疫苗市场正经历动态的市场格局，其特征是市场份额波动、竞争激烈的定价策略以及新产品的涌现。市场成长主要得益于对个人化医疗日益增长的需求以及疫苗技术的突破性创新。主要产业参与者正策略性地推出先进的治疗性疫苗，以满足多样化的医疗需求并扩大市场份额。治疗性疫苗市场的竞争异常激烈，主要企业竞相透过创新和策略联盟来争取主导。监管影响至关重要，严格的核准流程和合规标准会影响市场准入和扩张。北美和欧洲凭藉其强大的医疗保健基础设施和支持性的法规结构，处于市场领先地位。亚太地区正崛起为一个盈利的市场，这得益于医疗保健投资的增加和公众意识的提高。随着产业的不断发展，能够驾驭监管环境并充分利用技术进步的相关人员将拥有众多机会。

主要趋势和驱动因素：

受生物技术和个人化医疗进步的推动，治疗性疫苗市场正经历强劲成长。关键趋势包括针对癌症和自体免疫疾病等慢性疾病的疫苗研发。这些创新正将重点从传统的预防性疫苗转向治疗性应用，从而开闢新的治疗途径。 mRNA和病毒载体平台等尖端技术的整合正在加速开发更有效的疫苗。慢性疾病的日益增多和对标靶治疗需求的成长是推动该市场发展的关键因素。製药公司正在加大研发投入，以开发提供个人化治疗方案的疫苗。监管核准的增加以及生物技术公司与学术机构之间合作的加强也支持了这一趋势。在医疗基础设施正在发展的新兴市场，治疗性疫苗正获得认可，并展现出许多机会。能够成功应对监管环境并证明临床疗效的公司将占据有利地位。此外，免疫疗法的进步和联合治疗的日益普及预计将进一步推动市场成长。随着对个人化医疗的日益关注，治疗性疫苗市场预计将显着扩张。

限制与挑战：

治疗性疫苗市场面临许多显着的限制和挑战。其中一个关键挑战是疫苗研发高成本，需要对研发和临床试验进行大量投资。这种经济负担可能会阻碍中小企业的发展，并限制创新。监管障碍也构成重大阻碍，复杂的核准流程可能会延迟疫苗上市并增加成本。其他市场挑战包括公众认知和疫苗犹豫，这些因素会阻碍疫苗的接受度和广泛应用。物流配送的挑战，尤其是在资源匮乏的地区，进一步加剧了市场扩张的难度。确保低温运输完整性和覆盖偏远地区始终是需要克服的难题。最后，疾病流行程度的区域差异需要客製化疫苗解决方案，这使得标准化和扩充性变得更加复杂。所有这些因素共同构成了治疗性疫苗成长和广泛应用的重大挑战。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 癌症疫苗
    • 感染疾病疫苗
    • 自体免疫疾病疫苗
    • 神经系统疾病疫苗
  • 市场规模及预测：依产品划分
    • 预防性疫苗
    • 治疗性疫苗
  • 市场规模及预测：依技术划分
    • 重组技术
    • 结合疫苗
    • 活病毒疫苗
    • 灭活疫苗
    • 合成疫苗
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 感染疾病
    • 自体免疫疾病
    • 神经系统疾病
  • 市场规模及预测：依最终用户划分
    • 医院
    • 诊所
    • 研究所
    • 製药公司
  • 市场规模及预测：依组件划分
    • 抗原
    • 佐剂
  • 市场规模及预测：依製程划分
    • 临床前试验
    • 临床试验
    • 製造业
  • 市场规模及预测：依发展状况
    • 本地部署
    • 基于云端的
  • 市场规模及预测：按解决方案划分
    • 疫苗研发
    • 疫苗生产
    • 疫苗分发

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Inovio Pharmaceuticals
  • Bavarian Nordic
  • Hookipa Pharma
  • GlobeImmune
  • ImmunoVaccine Technologies
  • Valneva
  • OncoTherapy Science
  • Vaxil BioTherapeutics
  • CEL-SCI Corporation
  • Transgene
  • Agenus
  • Scancell Holdings
  • Oncolytics Biotech
  • Genocea Biosciences
  • Heat Biologics
  • BioNTech
  • Altimmune
  • VBI Vaccines
  • Imugene
  • Vaccibody

第九章：关于我们

简介目录
Product Code: GIS33227

Therapeutic Vaccines Market is anticipated to expand from $63.8 billion in 2024 to $176.8 billion by 2034, growing at a CAGR of approximately 10.7%. The Therapeutic Vaccines Market encompasses vaccines designed to treat existing diseases by stimulating the immune system to enhance its response. Unlike preventive vaccines, these target chronic infections, cancer, and autoimmune disorders. Advances in biotechnology and increasing prevalence of chronic diseases propel market growth. Key developments include personalized vaccines and novel delivery systems, addressing unmet medical needs and offering promising therapeutic prospects.

The Therapeutic Vaccines Market is experiencing robust growth, propelled by advances in immunotherapy and increasing prevalence of chronic diseases. The cancer vaccines segment leads in performance, driven by innovative treatments targeting tumor antigens. Prophylactic vaccines, particularly for HPV and hepatitis, are gaining momentum due to heightened awareness and prevention strategies. Infectious disease vaccines follow closely, with a focus on novel approaches for HIV and tuberculosis. Personalized vaccines are emerging as a promising area, offering tailored solutions based on individual genetic profiles. Adjuvant technologies are enhancing vaccine efficacy, contributing to market expansion. The rise of mRNA-based vaccines, exemplified by recent successes, underscores the potential for rapid development and deployment. The autoimmune disease vaccines sub-segment is also witnessing growth, as research into diseases like rheumatoid arthritis progresses. Strategic partnerships and collaborations among pharmaceutical companies are fostering innovation and accelerating clinical trials. Regulatory advancements and supportive policies further bolster market dynamics, paving the way for future opportunities.

Market Segmentation
TypeCancer Vaccines, Infectious Disease Vaccines, Autoimmune Disease Vaccines, Neurological Disorder Vaccines
ProductProphylactic Vaccines, Therapeutic Vaccines
TechnologyRecombinant Technology, Conjugate Vaccines, Live Attenuated Vaccines, Inactivated Vaccines, Synthetic Vaccines
ApplicationOncology, Infectious Diseases, Autoimmune Disorders, Neurological Disorders
End UserHospitals, Clinics, Research Institutes, Pharmaceutical Companies
ComponentAntigens, Adjuvants
ProcessPreclinical Testing, Clinical Trials, Manufacturing
DeploymentOn-premise, Cloud-based
SolutionsVaccine Development, Vaccine Manufacturing, Vaccine Distribution

Market Snapshot:

Therapeutic vaccines are experiencing a dynamic market landscape, characterized by evolving market share, competitive pricing strategies, and a surge in new product launches. The market's growth is propelled by increasing demand for personalized medicine and breakthrough innovations in vaccine technology. Key industry players are strategically introducing advanced therapeutic vaccines to cater to diverse medical needs, enhancing their market presence. Competition in the therapeutic vaccines market is intense, with major companies vying for dominance through innovation and strategic alliances. Regulatory influences play a vital role, as stringent approval processes and compliance standards impact market entry and expansion. North America and Europe are at the forefront, driven by robust healthcare infrastructure and supportive regulatory frameworks. The Asia-Pacific region is emerging as a lucrative market, fueled by rising healthcare investments and increasing awareness. As the industry evolves, opportunities abound for stakeholders who can navigate regulatory landscapes and leverage technological advancements.

Geographical Overview:

The therapeutic vaccines market is witnessing robust growth across various regions, each presenting unique opportunities. North America leads the charge, driven by substantial investments in biotechnology and a strong focus on research and development. The region's well-established healthcare infrastructure and supportive regulatory environment further bolster market expansion. Europe follows closely, with significant advancements in immunotherapy and a growing emphasis on personalized medicine. The region's commitment to innovation and collaboration among key stakeholders enhances its market position. In the Asia Pacific, the market is expanding rapidly, propelled by increasing healthcare expenditure and rising awareness of therapeutic vaccines. Countries like China and India are emerging as key players, with government initiatives supporting biotechnology advancements. Latin America and the Middle East & Africa are burgeoning markets with untapped potential. In Latin America, improved healthcare access and rising demand for advanced treatments drive growth. Meanwhile, the Middle East & Africa are recognizing the benefits of therapeutic vaccines in addressing regional health challenges.

Key Trends and Drivers:

The therapeutic vaccines market is experiencing robust growth, driven by advancements in biotechnology and personalized medicine. Key trends include the development of vaccines targeting chronic diseases such as cancer and autoimmune disorders. These innovations are shifting the focus from traditional prophylactic vaccines to therapeutic applications, offering new avenues for treatment. The integration of cutting-edge technologies like mRNA and viral vector platforms is accelerating the development of more effective vaccines. The rising prevalence of chronic diseases and the growing demand for targeted therapies are significant drivers for this market. Pharmaceutical companies are increasingly investing in research and development to create vaccines that offer personalized treatment options. This trend is supported by increasing regulatory approvals and collaborations between biotech firms and academic institutions. Opportunities abound in emerging markets where healthcare infrastructure is improving, and there is a growing awareness of therapeutic vaccines. Companies that can navigate regulatory landscapes and demonstrate clinical efficacy are well-positioned for success. Additionally, advancements in immunotherapy and the increasing acceptance of combination therapies are expected to further propel market growth. As the focus on personalized healthcare intensifies, the therapeutic vaccines market is poised for substantial expansion.

Restraints and Challenges:

The therapeutic vaccines market is confronted with several notable restraints and challenges. A primary challenge is the high cost of vaccine development, which necessitates substantial investment in research and clinical trials. This financial burden can deter smaller companies and limit innovation. Regulatory hurdles also present significant obstacles; navigating complex approval processes can delay market entry and increase costs. Additionally, the market faces issues with public perception and vaccine hesitancy, which can impede acceptance and uptake. The logistical challenges of distribution, especially in low-resource settings, further complicate market expansion. Ensuring cold chain integrity and reaching remote areas are persistent difficulties. Lastly, the variability in disease prevalence across regions necessitates tailored vaccine solutions, complicating standardization and scalability. These factors collectively pose significant challenges to the growth and accessibility of therapeutic vaccines.

Key Players:

Inovio Pharmaceuticals, Bavarian Nordic, Hookipa Pharma, GlobeImmune, ImmunoVaccine Technologies, Valneva, OncoTherapy Science, Vaxil BioTherapeutics, CEL-SCI Corporation, Transgene, Agenus, Scancell Holdings, Oncolytics Biotech, Genocea Biosciences, Heat Biologics, BioNTech, Altimmune, VBI Vaccines, Imugene, Vaccibody

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Component
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Cancer Vaccines
    • 4.1.2 Infectious Disease Vaccines
    • 4.1.3 Autoimmune Disease Vaccines
    • 4.1.4 Neurological Disorder Vaccines
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Prophylactic Vaccines
    • 4.2.2 Therapeutic Vaccines
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Recombinant Technology
    • 4.3.2 Conjugate Vaccines
    • 4.3.3 Live Attenuated Vaccines
    • 4.3.4 Inactivated Vaccines
    • 4.3.5 Synthetic Vaccines
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Oncology
    • 4.4.2 Infectious Diseases
    • 4.4.3 Autoimmune Disorders
    • 4.4.4 Neurological Disorders
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Clinics
    • 4.5.3 Research Institutes
    • 4.5.4 Pharmaceutical Companies
  • 4.6 Market Size & Forecast by Component (2020-2035)
    • 4.6.1 Antigens
    • 4.6.2 Adjuvants
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Preclinical Testing
    • 4.7.2 Clinical Trials
    • 4.7.3 Manufacturing
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 On-premise
    • 4.8.2 Cloud-based
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Vaccine Development
    • 4.9.2 Vaccine Manufacturing
    • 4.9.3 Vaccine Distribution

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Component
      • 5.2.1.7 Process
      • 5.2.1.8 Deployment
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Component
      • 5.2.2.7 Process
      • 5.2.2.8 Deployment
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Component
      • 5.2.3.7 Process
      • 5.2.3.8 Deployment
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Component
      • 5.3.1.7 Process
      • 5.3.1.8 Deployment
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Component
      • 5.3.2.7 Process
      • 5.3.2.8 Deployment
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Component
      • 5.3.3.7 Process
      • 5.3.3.8 Deployment
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Component
      • 5.4.1.7 Process
      • 5.4.1.8 Deployment
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Component
      • 5.4.2.7 Process
      • 5.4.2.8 Deployment
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Component
      • 5.4.3.7 Process
      • 5.4.3.8 Deployment
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Component
      • 5.4.4.7 Process
      • 5.4.4.8 Deployment
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Component
      • 5.4.5.7 Process
      • 5.4.5.8 Deployment
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Component
      • 5.4.6.7 Process
      • 5.4.6.8 Deployment
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Component
      • 5.4.7.7 Process
      • 5.4.7.8 Deployment
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Component
      • 5.5.1.7 Process
      • 5.5.1.8 Deployment
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Component
      • 5.5.2.7 Process
      • 5.5.2.8 Deployment
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Component
      • 5.5.3.7 Process
      • 5.5.3.8 Deployment
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Component
      • 5.5.4.7 Process
      • 5.5.4.8 Deployment
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Component
      • 5.5.5.7 Process
      • 5.5.5.8 Deployment
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Component
      • 5.5.6.7 Process
      • 5.5.6.8 Deployment
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Component
      • 5.6.1.7 Process
      • 5.6.1.8 Deployment
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Component
      • 5.6.2.7 Process
      • 5.6.2.8 Deployment
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Component
      • 5.6.3.7 Process
      • 5.6.3.8 Deployment
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Component
      • 5.6.4.7 Process
      • 5.6.4.8 Deployment
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Component
      • 5.6.5.7 Process
      • 5.6.5.8 Deployment
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Inovio Pharmaceuticals
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Bavarian Nordic
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Hookipa Pharma
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 GlobeImmune
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 ImmunoVaccine Technologies
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Valneva
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 OncoTherapy Science
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Vaxil BioTherapeutics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 CEL-SCI Corporation
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Transgene
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Agenus
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Scancell Holdings
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Oncolytics Biotech
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Genocea Biosciences
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Heat Biologics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 BioNTech
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Altimmune
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 VBI Vaccines
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Imugene
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Vaccibody
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us